Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [ 18F]-fluoro-azomycinarabino-furanoside ([ 18F]FAZA)

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Maier, Florian C ^a   Kneilling, Manfred ^a   Reischl, Gerald ^a   Cay, Funda ^a   Bukala, Daniel ^a   Schmid, Andreas ^a   Judenhofer, Martin S ^a   Röcken, Martin ^a   Machulla, Hans Jürgen ^a   Pichler, Bernd J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROAZOMYCINARABINOFURANOSIDE F 18; FLUORODEOXYGLUCOSE F 18; TRACER; UNCLASSIFIED DRUG; (18F) 1 ALPHA D (2 DEOXY 2 FLUOROARABINOFURANOSYL) 2 NITROIMIDAZOLE; (18F)-1-ALPHA-D-(2-DEOXY-2-FLUOROARABINOFURANOSYL)-2-NITROIMIDAZOLE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; NITROIMIDAZOLE DERIVATIVE; OXYGEN; RADIOPHARMACEUTICAL AGENT; RIBOSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; COLON CARCINOMA; CONTROLLED STUDY; DRUG CLEARANCE; DRUG UPTAKE; EX VIVO STUDY; FEMALE; HYPOXIA; MOUSE; NONHUMAN; OXYGEN BREATHING; POSITRON EMISSION TOMOGRAPHY; TUMOR HYPOXIA; TUMOR NECROSIS; ANIMAL; ANOXIA; BAGG ALBINO MOUSE; BREATHING; C57BL MOUSE; CELL HYPOXIA; DIAGNOSTIC IMAGING; EXPERIMENTAL NEOPLASM; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; SCINTISCANNING;

ANIMALS; ANOXIA; CELL HYPOXIA; DIAGNOSTIC IMAGING; FLUORINE RADIOISOTOPES; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NITROIMIDAZOLES; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RESPIRATION; RIBOSE;

EID: 82055164095     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-165     Document Type: Article

References (36)

1. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004, 14(3):198-206. 10.1016/j.semradonc.2004.04.008, 15254862.
2. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002, 7(6):492-508. 10.1634/theoncologist.7-6-492, 12490737.
3. Molls M, Stadler P, Becker A, Feldmann HJ, Dunst J. Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Strahlenther Onkol 1998, 174(Suppl 4):13-16.
4. Vaupel P, Mayer A. Hypoxia in cancer significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26(2):225-239. 10.1007/s10555-007-9055-1, 17440684.
5. Pauwels EK, Mariani G. Assessment of tumor tissue oxygenation agents, methods and clinical significance. Drug News Perspect 2007, 20(10):619-626. 10.1358/dnp.2007.20.10.1181355, 18301796.
6. Gagel B, Piroth M, Pinkawa M, et al. pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia?. BMC Cancer 2007, 7:113. 10.1186/1471-2407-7-113, 1948005, 17598907.
7. Lucignani G. PET imaging with hypoxia tracers: a must in radiation therapy. Eur J Nucl Med Mol Imaging 2008, 35(4):838-842. 10.1007/s00259-008-0740-2, 18264705.
8. Padhani A. PET imaging of tumour hypoxia. Cancer Imaging 2006, 6:S117-121. 1805075, 17114063.
9. Piert M, Machulla H, Becker G, et al. Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia. Eur J Nucl Med 1999, 26(2):95-109. 10.1007/s002590050365, 9933343.
10. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992, 22(1):199-212. 10.1016/0360-3016(92)91001-4, 1727119.
11. Dubois L, Landuyt W, Haustermans K, et al. Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer 2004, 91(11):1947-1954. 10.1038/sj.bjc.6602219, 2409764, 15520822.
12. Chapman JD, Zanzonico P, Ling CC. On measuring hypoxia in individual tumors with radiolabeled agents. J Nucl Med 2001, 42(11):1653-1655.
13. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36(2):417-428.
14. Piert M, Machulla HJ, Picchio M, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005, 46(1):106-113.
15. Sorger D, Patt M, Kumar P, et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003, 30(3):317-326. 10.1016/S0969-8051(02)00442-0, 12745023.
16. Dorow DS, Cullinane C, Conus N, et al. Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033. Eur J Nucl Med Mol Imaging 2006, 33(4):441-452. 10.1007/s00259-005-0039-5, 16450138.
17. Reischl G, Dorow DS, Cullinane C, et al. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results. J Pharm Pharm Sci 2007, 10(2):203-211.
18. Mannan RH, Somayaji VV, Lee J, Mercer JR, Chapman JD, Wiebe LI. Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. J Nucl Med 1991, 32(9):1764-1770.
19. Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging oxygenation of human tumours. Eur Radiol 2007, 17(4):861-872. 10.1007/s00330-006-0431-y, 1820761, 17043737.
20. Dence CS, Ponde DE, Welch MJ, Lewis JS. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer. Nucl Med Biol 2008, 35(6):713-720. 10.1016/j.nucmedbio.2008.06.001, 2661147, 18678357.
21. O'Donoghue JA, Zanzonico P, Pugachev A, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005, 61(5):1493-1502. 10.1016/j.ijrobp.2004.12.057, 15817355.
22. Matsumoto K, Szajek L, Krishna MC, et al. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography. Int J Oncol 2007, 30(4):873-881.
23. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2006, 47(6):989-998.
24. Machulla H-J. Imaging of Hypoxia: Tracer Developments. 1999, Dordrecht; Boston: Kluwer Academic.
25. Piert M, Machulla HJ, Becker G, Aldinger P, Winter E, Bares R. Dependency of the [18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. Nucl Med Biol 2000, 27(8):693-700. 10.1016/S0969-8051(00)00151-7, 11150699.
26. Shi K, Souvatzoglou M, Astner ST, et al. Quantitative assessment of hypoxia kinetic models by a cross-study of dynamic 18F-FAZA and 15O-H2O in patients with head and neck tumors. J Nucl Med 2010, 51(9):1386-1394. 10.2967/jnumed.109.074336, 20720045.
27. Maglione JE, Moghanaki D, Young LJ, et al. Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res 2001, 61(22):8298-8305.
28. Ellies LG, Fishman M, Hardison J, et al. Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. Int J Cancer 2003, 106(1):1-7. 10.1002/ijc.11178, 12794750.
29. Judenhofer MS, Wehrl HF, Newport DF, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med 2008, 14(4):459-465. 10.1038/nm1700, 18376410.
30. Ziegler A, Heidenreich R, Braumuller H, et al. EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion. Blood 2009, 113(15):3494-3502. 10.1182/blood-2008-08-175109, 19188665.
31. Bao Q, Newport D, Chen M, Stout DB, Chatziioannou AF. Performance evaluation of the inveon dedicated PET preclinical tomograph based on the NEMA NU-4 standards. J Nucl Med 2009, 50(3):401-408. 10.2967/jnumed.108.056374, 2803022, 19223424.
32. Iwaki T. A Color Atlas of Sectional Anatomy of the Mouse. 2001, Adthree Publishing Company Limited.
33. Davenport HA. Histological and Histochemical Technics. 1960, W.B. Saunders Company, Philadelphia, PA.
34. Busk M, Munk OL, Jakobsen S, et al. Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET. Acta Oncol 2010, 49(7):922-933. 10.3109/0284186X.2010.503970, 20831479.
35. Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 2008, 35(12):2294-2303. 10.1007/s00259-008-0888-9, 18682937.
36. Mortensen LS, Busk M, Nordsmark M, et al. Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: a preclinical study. Radiother Oncol 2011, 99(3):418-423. 10.1016/j.radonc.2011.06.034, 21723634.